Nantahala Capital Management LLC Has $13.89 Million Stock Position in Fulcrum Therapeutics, Inc. $FULC

Key Points

• Nantahala Capital Management LLC increased its stake in Fulcrum Therapeutics by 0.9%, owning approximately 8.93% of the company, which is valued at $13.89 million.
• Fulcrum Therapeutics stock has experienced a downturn, currently priced at $6.48 with a decline of 2.6% recently.
• Analysts have mixed ratings on Fulcrum Therapeutics, with a consensus rating of "Moderate Buy" and a price target averaging $7.57.

Nantahala Capital Management LLC raised its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 0.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,822,693 shares of the company's stock after purchasing an additional 42,985 shares during the period. Fulcrum Therapeutics makes up about 0.6% of Nantahala Capital Management LLC's portfolio, making the stock its 24th largest holding. Nantahala Capital Management LLC owned approximately 8.93% of Fulcrum Therapeutics worth $13,889,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Suvretta Capital Management LLC boosted its holdings in Fulcrum Therapeutics by 182.3% in the 4th quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company's stock valued at $15,691,000 after purchasing an additional 2,155,675 shares during the period. Woodline Partners LP lifted its holdings in shares of Fulcrum Therapeutics by 110.3% during the 4th quarter. Woodline Partners LP now owns 1,410,520 shares of the company's stock worth $6,629,000 after acquiring an additional 739,713 shares during the period. Northern Trust Corp lifted its holdings in shares of Fulcrum Therapeutics by 25.1% during the 4th quarter. Northern Trust Corp now owns 710,321 shares of the company's stock worth $3,339,000 after acquiring an additional 142,578 shares during the period. Shay Capital LLC lifted its holdings in shares of Fulcrum Therapeutics by 4.2% during the 4th quarter. Shay Capital LLC now owns 301,464 shares of the company's stock worth $1,417,000 after acquiring an additional 12,227 shares during the period. Finally, Nuveen LLC bought a new stake in shares of Fulcrum Therapeutics during the 1st quarter worth approximately $441,000. Institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Stock Up 5.5%

NASDAQ FULC traded up $0.36 on Thursday, hitting $6.88. The company's stock had a trading volume of 431,746 shares, compared to its average volume of 573,079. Fulcrum Therapeutics, Inc. has a 1-year low of $2.32 and a 1-year high of $9.30. The company's 50-day moving average is $7.06 and its 200 day moving average is $5.42. The firm has a market cap of $372.15 million, a PE ratio of -5.64 and a beta of 2.82.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.01. On average, equities analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on FULC. Leerink Partners raised shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $4.00 to $12.00 in a report on Friday, May 23rd. Wall Street Zen downgraded shares of Fulcrum Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Royal Bank Of Canada upped their price target on shares of Fulcrum Therapeutics from $4.00 to $5.00 and gave the stock a "sector perform" rating in a report on Wednesday, July 30th. Cantor Fitzgerald raised shares of Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price target for the company in a report on Thursday, May 15th. Finally, Leerink Partnrs raised shares of Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Friday, May 23rd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.57.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.